A detailed history of Dimensional Fund Advisors LP transactions in Exagen Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 29,787 shares of XGN stock, worth $164,424. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,787
Previous 21,039 41.58%
Holding current value
$164,424
Previous $38,000 142.11%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$1.74 - $3.42 $15,221 - $29,918
8,748 Added 41.58%
29,787 $92,000
Q2 2024

Aug 09, 2024

SELL
$1.36 - $2.05 $7,341 - $11,065
-5,398 Reduced 20.42%
21,039 $38,000
Q1 2024

May 10, 2024

SELL
$1.42 - $2.3 $13,622 - $22,063
-9,593 Reduced 26.63%
26,437 $42,000
Q4 2023

Feb 07, 2024

SELL
$1.45 - $2.39 $26,635 - $43,901
-18,369 Reduced 33.77%
36,030 $71,000
Q3 2023

Nov 09, 2023

SELL
$2.24 - $2.93 $30,154 - $39,443
-13,462 Reduced 19.84%
54,399 $131,000
Q2 2023

Aug 09, 2023

BUY
$2.36 - $3.48 $6,145 - $9,061
2,604 Added 3.99%
67,861 $196,000
Q4 2022

Feb 09, 2023

SELL
$2.1 - $3.4 $11,033 - $17,863
-5,254 Reduced 7.45%
65,257 $156,000
Q3 2022

Nov 10, 2022

BUY
$2.69 - $8.68 $4,567 - $14,738
1,698 Added 2.47%
70,511 $191,000
Q2 2022

Aug 12, 2022

SELL
$4.18 - $7.74 $13,534 - $25,062
-3,238 Reduced 4.49%
68,813 $395,000
Q1 2022

May 13, 2022

BUY
$7.12 - $11.06 $171,150 - $265,860
24,038 Added 50.07%
72,051 $579,000
Q4 2021

Feb 09, 2022

BUY
$8.97 - $14.08 $132,917 - $208,637
14,818 Added 44.64%
48,013 $558,000
Q3 2021

Nov 12, 2021

BUY
$10.25 - $15.21 $195,108 - $289,522
19,035 Added 134.43%
33,195 $451,000
Q2 2021

Aug 12, 2021

BUY
$12.4 - $17.92 $175,584 - $253,747
14,160 New
14,160 $212,000

Others Institutions Holding XGN

About EXAGEN INC.


  • Ticker XGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 16,260,400
  • Market Cap $89.8M
  • Description
  • Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...
More about XGN
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.